Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
PROF · NASDAQ · Surgical & Medical Instruments & Apparatus
Profound Medical (PROF) · oqro.io/stocks/PROF · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$7.42−0.02 (−0.27%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
No open-market purchase by an insider of Profound Medical was filed in the last 90 days. The latest on record was on May 20, 2025.
Since 2025, Profound Medical insiders reported 2 open-market purchases and 0 sales on Forms 4 and 5, with purchases in 1 different year, most recently 2025.
No open-market sale by an insider of Profound Medical (PROF) was filed with the SEC in the last 90 days.
No trade in Profound Medical (PROF) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+16.9% (+$1.07) from Nov 13, 2025 to Nov 13, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $6.35 on Nov 13, 2025 to $7.42 on Nov 13, 2026 (+16.9%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Surgical & Medical Instruments & Apparatus company based in Mississauga, A6.
Last 12 months
+16.9%
Market value
$272M
S&P 500 +12.3% over the same dates. Prices adjusted for splits and dividends.
Short interest: 1.58M shares sold short (4.3% of shares outstanding), +1.4% vs the previous count, 9.8 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$9.83M
+85.9% vs the same quarter a year earlier
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net cash
$28.8M
Debt $4.51M, cash $33.3M, at Sep 30, 2026
Net income, last 12 months
−$32.5M
Operating profit covers interest -105.8x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 5, 2026.
Revenue, fiscal 2025
$16.1M
+50.7% vs the year before
Net income, fiscal 2025
−$42.6M
A loss for the year
Shares outstanding
36.6M
As of Nov 5, 2026
Traded May 15 – May 16, 2025 · largest single transaction ~$57K
May 16, 2025~$57K · 12K sh @ $4.73
May 15, 2025~$43K · 10K sh @ $4.33
DetailsOfficial recordTraded Jan 14 – Jan 27, 2020 · disclosed 577 to 590 days laterLate
Jan 27, 2020$1,001–$15,000Late
DetailsOfficial recordJan 14, 2020$1,001–$15,000Late
DetailsOfficial recordCongress
Traded Jul 21, 2020 · disclosed 227 days laterLate
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insiders of Profound Medical reported 2 open-market purchases and 0 sales since 2025; purchases in 2025.
| Year | Bought | Sold |
|---|---|---|
| 2025 | $100K2×2 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Against the S&P 500 over the year
Since Nov 12, 2025, PROF is up 14.7% and the index fund is up 10.4%: 4 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much PROF moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
Top officer leaving
“Fabian, the Company’s current President, is appointed President and Chief Executive Officer of the Company, effective as of the Transition Date, and Arun Menawat will step down as Chief Executive Officer and will become Executive Chairman of the Board as of the Transition Date.”
8-K on sec.govTop officer leaving
“Separation Agreement and Contractor Services Agreement On August 14, 2026, Rashed Dewan resigned from his position as Chief Financial Officer of the Company, effective the same day (the “Separation Date”).”
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
